20 April 2018
TeleMD, a Russian start-up, is developing a software platform that uses artificial intelligence (AI) for cancer diagnostics and prognostication.
Over the past few months the start-up has been focused on fine-tuning the platform’s image recognition functionality for cancer diagnostics, and also on making the solution scalable for medical specialists from across disciplines to be able to analyze heterogeneous medical data.
The TeleMD platform is designed to enable physicians to diagnose and predict oncologic developments in complicated cases by analyzing medical images and other patient-specific data. With the solution, doctors may expect to be able to reach out to broader medical communities and get remote advice. TeleMD is reported to have developed its diagnostics criteria and algorithms in close collaboration with experts from the Moscow-based Russian Blokhin Research Center for Oncology and some other leading scientific hubs and clinical centers.
Last September the start-up received more than $180,000 for the software platform from Primer Capital, a Russian VC fund focused on biotech.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024